Saint Marcel Campes

Acute hypoxemic respiratory failure often requires endotracheal intubation and invasive mechanical ventilation due to severe low oxygen levels or signs of respiratory distress. While these interventions help reduce breathing effort and improve oxygen levels, they can also cause side effects like muscle weakness, lung injury, infections, and blood pressure problems. The study is comparing two main approaches to intubation to find the best balance between early intubation to prevent organ damage and delayed intubation to avoid ventilation-related complications. The trial compares a liberal intubation strategy, which recommends intubation if oxygen levels fall below a certain threshold (SpO2/FiO2 < 110) or if restrictive criteria are met, against a restrictive strategy that recommends intubation only when more severe signs persist, such as very low oxygen levels (SpO2/FiO2 < 88), high respiratory rate, or neurological and hemodynamic impairments. Intubation decisions are based on clinical criteria lasting more than 5 minutes. Participants will be adults admitted to intensive care within the last 24 hours with acute respiratory failure meeting specific oxygen therapy requirements. Researchers will monitor the duration of organ support and mortality up to 28 days to evaluate the impact of each intubation strategy. The study also involves informed consent and excludes patients with other respiratory or neurological conditions, recent mechanical ventilation, or treatment limitations.

Researchers are studying the presence of seronegative auto-immune hepatitis and its possible link to disease severity. Severity is defined by dependence on corticosteroids, resistance to corticosteroids, and severe disease forms at diagnosis such as cirrhosis or fulminant hepatitis. If seronegative cases are common, the study will also search for other auto-antibodies related to this autoimmune hepatitis. The study involves patients from the Guadeloupean constitutive center of rare diseases (CCRD Filfoie) and Saint-Antoine hospital. Both retrospective analysis of existing patients and prospective follow-up of new patients will be conducted. As part of the study, blood samples will be collected to build a serological library to identify rare auto-antibodies that may serve as prognostic markers. Participants will have their medical history reviewed and undergo blood sampling to collect serological data. Researchers will analyze tissue samples through histological rereading of seronegative autoimmune hepatitis at baseline. The study will monitor disease severity based on clinical criteria and antibody presence. Patients will be followed over time to better understand the relationship between seronegativity and disease outcomes.

Numerous neurological disorders affecting the central and peripheral nervous system are linked to immune system activity. This research focuses on rare neuroimmune conditions such as Autoimmune Encephalitis (AE) and Paraneoplastic Neurological Syndromes (PNS). Improving diagnosis speed and accuracy for these disorders may help guide better treatment approaches in the future. Participants provide biological samples including blood and cerebrospinal fluid (CSF) for the study. Blood samples are collected once to obtain serum, buffy coat, plasma, and peripheral blood mononuclear cells (PBMC). If CSF is drawn for diagnosis, any leftover sample is also stored. Samples are collected and stored to support better diagnosis and research. During the study, participants contribute blood and possibly CSF samples which will be stored and analyzed over a long term, up to 10 years. Researchers will monitor these biological materials to better understand the disorders and develop improved diagnostic tools and treatments. The study involves consented patients with neurological disorders related to PNS or AE and may include antibody testing results.

Researchers are evaluating VX-147 for its effectiveness, safety, tolerability, and how the body processes it in adults and children aged 10 to 65 who have apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease. This study is a Phase 2/3 trial designed to better understand treatment options for this specific kidney condition. Participants will receive either VX-147 or a placebo, both given as oral tablets. The study is double-blind and placebo-controlled, meaning neither participants nor researchers know who receives the active drug or placebo during the treatment period. The trial consists of two parts: Part A focuses on treatment effects over at least 48 weeks, while Part B involves continued safety and tolerability observation for approximately four years after the last participant enrolls. Throughout the study, participants will undergo regular assessments including measurements of urine protein to creatinine ratio and kidney function via estimated glomerular filtration rate (eGFR). Safety is monitored by tracking adverse events and serious adverse events. Data will be collected during the treatment period and followed long-term to evaluate both efficacy and safety outcomes, with some measures assessed at interim and final analyses over at least two years.

Researchers are evaluating the use of olaparib in adult male patients with metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting across multiple centers in France. This observational longitudinal study aims to understand how olaparib is used in treatment sequences, its effectiveness, safety, and patterns of BRCA genetic testing to help improve future clinical care for this condition. The study includes patients who have started olaparib treatment within the last two months before joining the study or who participated in an early access program funded for olaparib use. Treatment decisions are made by the patients' physicians, and researchers observe and collect data without intervening. The study follows patients for up to 24 months from the start of olaparib treatment to track how long they continue the treatment and other outcomes. Participants will be monitored through their routine medical care, and data will be collected on treatment duration, safety, and BRCA testing patterns. The main outcome measured is the time until patients stop olaparib treatment, observed over a period of up to two years. The study relies on patient records and does not involve additional experimental procedures, focusing on real-life treatment experiences and outcomes.

Researchers are evaluating two treatment strategies for patients with intermediate-risk differentiated thyroid cancer. The study compares systematic radioiodine administration to a treatment approach guided by a post-operative assessment based on serum thyroglobulin (Tg) levels and diagnostic radioiodine (RAI) scintigraphy. This is a phase III multicenter trial aiming to determine which strategy leads to a better tumor response over 36 months. Participants are assigned to one of two groups: one receives a systematic RAI treatment with a fixed dose of either 3.7 GBq or 1.1 GBq of iodine-131 after stimulation with recombinant human TSH (rhTSH). The other group's treatment decision depends on specific post-operative criteria including Tg levels and RAI scintigraphy results, leading to no treatment or adjusted doses of RAI ranging from 1.1 GBq to 3.7 GBq depending on findings such as metastatic lymph nodes or distant metastases. During the study, patients are monitored for tumor response and safety over 36 months following randomization. Assessments include serum Tg measurements, diagnostic RAI scintigraphy, neck ultrasounds, and cytology when needed. Patients are followed annually for up to five years to track outcomes and adverse events. Treatment adherence and clinical status will be regularly evaluated as part of the comprehensive follow-up plan.